



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Ref. PDL: SCY: OCT: 2011-2012/

Dated: 31st October, 2011

The National Stock Exchange of India Limited,
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra (East),
Mumbai (Maharashtra)

Subject: Press Release

Dear Sir,

Please find enclosed herewith press release with respect to official accreditation received by the Company from the Japan's Ministry of Health, Labour and Welfare enabling the Company to manufacture and supply **Cephalosporin non sterile drugs** to the Japanese Market.

You are requested to kindly display the same on the Notice Board of your exchange for the information of members and general Public.

Thanking you,

Yours faithfully,
For Parabolic Drugs Limited,

Vice President and Company Secretary

Enclosed: As Above.

Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 **Fax :** +91-172-3914645

Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India **Tel. :** +91-1733-256380

website : www.parabolicdrugs.com

Parabolic Drugs gets Japanese nod for Cephalosporin Drugs

Receives Accreditation as a Foreign Drugs manufacturer from Japanese PMDA

The Company has received an official accreditation from Japan's ministry of Health, Labour and Welfare, enabling it to manufacture and supply Cephalosporin non sterile drugs to the Japanese market.

The 5-year accreditation has been awarded to PDL's manufacturing site at Derabassi in Punjab and is in accordance with Article 13-3 of the *Pharmaceutical Affairs Act*, which classifies Parabolic Drugs as a certified foreign drug manufacturer.

Japan, the second single largest drug market in the world is also a leading nation in terms of pharma research, technology, machinery and medical research and is valued at USD 107 billion in 2010. The Japanese certification denotes the Company's technical capability in the non-sterile market and also differentiates it from many of its competitors.□□

The EU GMP accredited Derabassi facility is a dedicated Cephalosporin manufacturing site that is spread across 27 Acres and has an annual capacity over 900 Tons of Cephalosporin. This accreditation is an essential element of Company's regulatory market vision as the Japanese market is an arena it hopes to heighten its market presence.

The Company sees an opportunity in building its regulated market business in the \$21 Billion Global Cephalosporin Molecule market and has over 38 DMFs filed across EU, Canada and USA. It also has over 3 molecules in pipeline for filing it in Japan. In the FY 11, the Company's exports accounted for 36.98% of the total revenues, with direct exports alone accounting to 28.21%.

